The disease landscape has shifted majorly over the past few decades. Drugs have exterminated most of the infectious life-threatening diseases of the past. However, today our lifestyle choices have given rise to several non-communicable diseases (NCDs). Diabetes, cardiovascular disease, musculoskeletal disease, and cancer are all examples of common NCDs prevalent today. According to the World Health Organization, NCDs contributed to 41 million deaths worldwide in 2021. Out of these, 15 million people were between the age group of 30 to 69 years. 85% of such "premature" deaths occur in low- and middle-income countries. Conventional drugs may come in handy to ease the symptoms of NCDs for some time, but they do not guarantee a definite chance of cure. Drugs treat the symptoms of the disease, however, not the cause. This increases the disease burden among patients, followed by extensive healthcare costs. There is an urgent need for modification of treatment approaches for the management of diseases prevalent today.

Key companies like Sanofi, Pfizer, Inc., Takeda Pharmaceutical Company, Bristol-Myers Squibb, Novartis, Gilead, Merck, Roche, etc invest heavily in the development of regenerative therapies due to their immense therapeutic potential. Moreover, collaborative product development strategies have become a trend in the regenerative sector. The key players are focused on expanding their spectrum of research by acquiring smaller R&D companies. The market has witnessed a significant number of mergers & acquisitions in recent years. For instance, Pro-Kidney, a cell therapy company, is going public in a SPAC (Special Purpose Acquisition Company) merger that infuses the biotech with $825 million for its autologous cell therapy for chronic kidney disease. In 2021, Swiss pharma giant Novartis acquired all the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics. The arrival of well-established pharmaceutical organizations is expected to increase M&A (Mergers and Acquisitions) activities, which will boost growth in the regenerative medicine market.